Ayşe Rumeysa Aydoğan Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayşe Rumeysa Aydoğan Demir has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Güzin Demirağ
Faculty of Medicine, Department of Medical Oncology, Ondokuz Mayıs University, Samsun, Turkey
2 shared publications - Mehmet Kefeli
Faculty of Medicine, Department of Pathology, Ondokuz Mayıs University, Samsun, Turkey
2 shared publications - Teyfik Demir
Faculty of Medicine, Department of Medical Oncology, Ondokuz Mayıs University, Samsun, Turkey
2 shared publications - Ahmet Zengin
Department of Obstetrics and Gynecology, Umraniye Training and Research Hospital, Istanbul, Turkey
1 shared publication - Anıl Koçman
En yüksek alt kategorisini oluşturmakta olup Cerrahi Onkoloji Bölümü Patoloji Bölümü Avrupa Kanser Jinekolojik Onkoloji Cerrahisi Bölümü
1 shared publication - Arife Ebru Taşcı
Department of Gynecologic Oncology, Ankara Bilkent City Hospital, University of Health Sciences, 06800 Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in BMC Cancer
Prognostic and clinicopathologic significance of the tumor–stroma ratio in pure endometrial serous carcinoma
- 13 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessPrognostic and clinicopathologic significance of the tumor–stroma ratio in pure endometrial serous carcinoma
- Open Access
- 4 September 2026
- Published by Springer Nature in BMC Cancer
Prognostic significance of folate receptor alpha expression in endometrial serous carcinoma: implications for patient stratification and targeted therapy
Objective: To evaluate the clinical significance of folate receptor alpha (FRα) expression in endometrial serous carcinoma. Methods: We retrospectively analyzed 47 patients with histopathologically confirmed endometrial serous carcinoma who underwent hysterectomy and received systemic therapy. FRα expression was assessed by immunohistochemistry and categorized as high or low based on ≥ 25% of tumor cells showing moderate-to-strong membranous staining. Associations with clinicopathological variables and survival outcomes were evaluated. Results: High FRα expression was observed in 29.8% of cases and was not associated with clinicopathological variables. Patients with high FRα expression had significantly shorter progression-free survival compared with those with low expression (median, 14 vs. 54 months; p = 0.007). In multivariable Cox regression analysis for PFS, high FRα expression remained independently associated with shorter PFS (HR 3.91, 95% CI 1.54–9.94, p = 0.004). No statistically significant difference in overall survival was observed ( p = 0.08). Conclusion: High FRα expression was associated with shorter progression-free survival in endometrial serous carcinoma. These findings suggest that FRα expression may represent a biologically relevant marker associated with disease progression and support further investigation in molecularly characterized cohorts.
- 4 September 2026
- Published by Springer Nature in BMC Cancer
Open AccessPrognostic significance of folate receptor alpha expression in endometrial serous carcinoma: implications for patient stratification and targeted therapy
Objective: To evaluate the clinical significance of folate receptor alpha (FRα) expression in endometrial serous carcinoma. Methods: We retrospectively analyzed 47 patients with histopathologically confirmed endometrial serous carcinoma who underwent hysterectomy and received systemic therapy. FRα expression was assessed by immunohistochemistry and categorized as high or low based on ≥ 25% of tumor cells showing moderate-to-strong membranous staining. Associations with clinicopathological variables and survival outcomes were evaluated. Results: High FRα expression was observed in 29.8% of cases and was not associated with clinicopathological variables. Patients with high FRα expression had significantly shorter progression-free survival compared with those with low expression (median, 14 vs. 54 months; p = 0.007). In multivariable Cox regression analysis for PFS, high FRα expression remained independently associated with shorter PFS (HR 3.91, 95% CI 1.54–9.94, p = 0.004). No statistically significant difference in overall survival was observed ( p = 0.08). Conclusion: High FRα expression was associated with shorter progression-free survival in endometrial serous carcinoma. These findings suggest that FRα expression may represent a biologically relevant marker associated with disease progression and support further investigation in molecularly characterized cohorts.
- Open Access
- 10 November 2025
- Published by Academician Publishing
Olgularla Kadın Hastalıkları ve Doğum II
- 10 November 2025
- Published by Academician Publishing
Open AccessOlgularla Kadın Hastalıkları ve Doğum II
- Open Access
- 10 November 2025
- Published by Academician Publishing
- p. 159-166
Kemik İliği Transplantasyonu Sonrası Graft-Versus-Host Hastalığı ile İlişkili Vajinal Stenoz
Graft versus host hastalığı (GVHD) normal dokuya karşı immünolojik bir reaksiyondur ve allojenik kök hücre naklinin bir komplikasyonu olarak ortaya çıkabilir. Genital GVHD, allojenik kemik iliği transplantasyonunun (KİT) daha az bilinen ve muhtemelen hafife alınan bir komplikasyonudur (1). GVHD' e neden olan mekanizma graft hücrelerin konakçı hücrenin anjijenlerine karşı geliştirdiği T lenfosit immun cevabıdır (2). GVHD akut veya kronik olabilir. Akut GVHD nakilden sonraki ilk 100 günde, kronik GVHD ise 100 günden sonra meydana gelir (3). GVHD cilt, mukoza, gastrointestinal sistem, karaciğer ve akciğer tutulumu ile seyreden heterojen klinik bulgular gösterir. Kadınlarda GVHD ilişkili immunolojik reaksiyonlara sekonder genital sistemde sklerotik değişiklikler ve mukoza anormallikleri meydana gelebilir (4). Genital GVHD tedavisinde, topikal östrojen preparatları, güçlü topikal kortikosteroidler, immünmodülatör ajanlar, vajinal dilatatörler gibi yöntemler ilk basamakta yer alır. Semptomların ilerlediği veya vajinal stenozun geliştiği olgularda cerrahi müdahale gündeme gelebilir (
- 10 November 2025
- Published by Academician Publishing
- p. 159-166
Open AccessKemik İliği Transplantasyonu Sonrası Graft-Versus-Host Hastalığı ile İlişkili Vajinal Stenoz
Graft versus host hastalığı (GVHD) normal dokuya karşı immünolojik bir reaksiyondur ve allojenik kök hücre naklinin bir komplikasyonu olarak ortaya çıkabilir. Genital GVHD, allojenik kemik iliği transplantasyonunun (KİT) daha az bilinen ve muhtemelen hafife alınan bir komplikasyonudur (1). GVHD' e neden olan mekanizma graft hücrelerin konakçı hücrenin anjijenlerine karşı geliştirdiği T lenfosit immun cevabıdır (2). GVHD akut veya kronik olabilir. Akut GVHD nakilden sonraki ilk 100 günde, kronik GVHD ise 100 günden sonra meydana gelir (3). GVHD cilt, mukoza, gastrointestinal sistem, karaciğer ve akciğer tutulumu ile seyreden heterojen klinik bulgular gösterir. Kadınlarda GVHD ilişkili immunolojik reaksiyonlara sekonder genital sistemde sklerotik değişiklikler ve mukoza anormallikleri meydana gelebilir (4). Genital GVHD tedavisinde, topikal östrojen preparatları, güçlü topikal kortikosteroidler, immünmodülatör ajanlar, vajinal dilatatörler gibi yöntemler ilk basamakta yer alır. Semptomların ilerlediği veya vajinal stenozun geliştiği olgularda cerrahi müdahale gündeme gelebilir (